Advertisement

Computed tomography assessment of evolution of interstitial lung disease in systemic sclerosis: Comparison of two scoring systems

Published:February 20, 2020DOI:https://doi.org/10.1016/j.ejim.2020.02.009

      Highlights

      • Chest HRCT allows quantification of ILD both by visual and computed-aided methods.
      • Computed-aided method shows a better performance than the visual scoring system.
      • Computed-aided method improves sensitivity and repeatability of quantitative changes.
      • Computed-aided method is easier and faster to perform.

      Abstract

      Background

      The aim of this study was to evaluate and compare the internal and external responsiveness of a computed-aided method (CaM) with a conventional visual reader-based score (CoVR) to measure interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) on high resolution computed tomography (HRCT).

      Methods

      Forty-five patients were evaluated in this retrospective cohort. HRCTs were collected at baseline and after 1 year. HRCT abnormalities were evaluated according to a CoVR (Warrick's method) and a quantitative CaM. Internal 1-year responsiveness was tested with a standardized mean response (SRM). Analyses of the receiver operating characteristic curves (ROCs) evaluated the sensitivity and specificity of the two methods to discriminate between clinically relevant progression and no relevant progression, using expert judgment as the gold standard (external responsiveness).

      Results

      In one year, lung involvement was stable/improved in 17 of the 45 patients (37.8%) and worsened in 28 patients (62.2%). HRCT scores changed moderately over the follow-up period. Using SFM, CaM was significantly more responsive in detecting changes due to treatment than the CoVR method. Likewise, in the analysis of the ROC curve, CaM scores showed the highest performance (AUC ROC CaM vs. CoVR, 0.951 vs. 0.807; p = 0.0065).

      Conclusion

      Quantitative analysis of CaM was more responsive than the CoVR method to accurately evaluate and monitor SSc-ILD progression or response to therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Allanore Y.
        • Simms R.
        • Distler O.
        • Trojanowska M.
        • Pope J.
        • Denton C.P.
        • et al.
        Systemic sclerosis.
        Nat Rev Dis Primers. 2015; 23: 15002
        • Elhai M.
        • Meune C.
        • Avouac J.
        • Kahan A.
        • Allanore Y
        Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.
        Rheumatology (Oxford). 2012; 51: 1017-1026
        • Walker U.A.
        • Tyndall A.
        • Czirják L.
        • Denton C.
        • Farge-Bancel D.
        • Kowal-Bielecka O.
        • et al.
        Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the Eular Scleroderma trials and research group database.
        Ann Rheum Dis. 2007; 66: 754-763
        • Patiwetwitoon S.
        • Wangkaew S.
        • Euathrongchit J.
        • Kasitanon N.
        • Louthrenoo W
        High-resolution computed tomographic findings in systemic sclerosis-associated interstitial lung disease: comparison between diffuse and limited systemic sclerosis.
        J Clin Rheumatol. 2012; 18: 229-233
        • Goldin J.G.
        • Lynch D.A.
        • Strollo D.C.
        • Suh R.D.
        • Schraufnagel D.E.
        • Clements P.J.
        • et al.
        High resolution CT findings in scleroderma-related lung diseases: findings from scleroderma lung study.
        Chest. 2008; 134: 358-367
        • Kim E.A.
        • Johkoh T.
        • Lee K.S.
        • Ichikado K.
        • Koh E.M.
        • Kim T.S.
        • et al.
        Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation.
        J Comput Assist Tomogr. 2001; 25: 757-763
        • Diot E.
        • Boissinot E.
        • Asquier E.
        • Guilmot J.L.
        • Lemarié E.
        • Valat C.
        • et al.
        Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis.
        Chest. 1998; 114: 1623-1629
        • Warrick J.H.
        • Bhalla M.
        • Schabel S.I.
        • Silver R.M
        High resolution computed tomography in early scleroderma lung disease.
        J Rheumatol. 1991; 18: 1520-1528
        • Goh N.
        • Desai S.R.
        • Veeraraghavan S.
        • Hansell D.M.
        • Copley S.J.
        • Maher T.M.
        • et al.
        Interstitial lung disease in systemic sclerosis: a simple staging system.
        Am J Respir Crit Care Med. 2008; 177: 1248-1254
        • Kim H.J.
        • Li G.
        • Gjertson D.
        • Elashoff R.
        • Shah S.K.
        • Ochs R.
        • et al.
        Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study.
        Acad Radiol. 2008; 15: 1004-1016
        • Yabuuchi H.
        • Matsuo Y.
        • Tsukamoto H.
        • Horiuchi T.
        • Sunami S.
        • Kamitani T.
        • et al.
        Evaluation of the extent of ground-glass opacityon high-resolution ct in patients with interstitial pneumonia associated with systemic sclerosis: comparison between quantitative and qualitative analysis.
        Clin Radiol. 2014; 69: 758-764
        • Kim H.G.
        • Tashkin D.P.
        • Clements P.J.
        • Li G.
        • Brown M.S.
        • Elashoff R.
        • et al.
        A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.
        Clin Exp Rheumatol. 2010; 28: S26-S35
        • Ariani A.
        • Carotti M.
        • Gutierrez M.
        • Bichisecchi E.
        • Grassi W.
        • Giuseppetti G.M.
        • et al.
        Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: preliminary results.
        Rheumatol Int. 2014; 34: 511-516
        • Salaffi F.
        • Carotti M.
        • Bosello S.
        • Ciapetti A.
        • Gutierrez M.
        • Bichisecchi E.
        • et al.
        Computer-aided quantification of interstitial lung disease from high resolution computed tomography images in systemic sclerosis: correlation with visual reader-based score and physiologic tests.
        Biomed Res Int. 2015; 2015834262
        • Salaffi F.
        • Carotti M.
        • Di Donato E.
        • Di Carlo M.
        • Ceccarelli M.
        • Giuseppetti G
        Computer-Aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability.
        PLoS One. 2016; 11e0149240
        • Tashkin D.P.
        • Elashoff R.
        • Clements P.J.
        • Goldin J.
        • Roth M.D.
        • Furst D.E.
        • et al.
        Cyclophosphamide versus placebo in scleroderma lung disease.
        N Engl J Med. 2006; 354: 2655-2666
        • Roth M.D.
        • Tseng C.H.
        • Clements P.J.
        • Furst D.E.
        • Tashkin D.P.
        • Goldin J.G.
        • et al.
        Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.
        Arthritis Rheum. 2011; 63: 2797-2808
        • Kim H.J.
        • Tashkin D.P.
        • Gjertson D.W.
        • Brown M.S.
        • Kleerup E.
        • Chong S.
        • et al.
        Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.
        Ann Rheum Dis. 2016; 75: 1367-1371
        • van den Hoogen F.
        • Khanna D.
        • Fransen J.
        • Johnson S.R.
        • Baron M.
        • Tyndall A.
        • et al.
        classification criteria for systemic sclerosis: an American college of Rheumatology/European League against Rheumatism collaborative initiative.
        Arthritis Rheum. 2013; 65 (2013): 2737-2747
        • LeRoy E.C.
        • Black C.
        • Fleischmajer R.
        • Jablonska S.
        • Krieg T.
        • Medsger T.A.
        • et al.
        Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.
        J Rheumatol. 1988; 15: 202-205
        • Shin K.E.
        • Chung M.J.
        • Jung M.P.
        • Choe B.K.
        • Lee K.S
        Quantitative computed tomographic indexes in diffuse interstitial lung disease: correlation with physiologic tests and computed tomography visual scores.
        J Comput Assist Tomogr. 2011; 35: 266-271
        • Husted J.A.
        • Cook R.J.
        • Farewell V.T.
        • Gladmann D.D
        Methods for assessing responsiveness: a critical review and recommendations.
        J Clin Epidemiol. 2000; 53: 459-468
        • Revicki D.
        • Hays R.D.
        • Cella D.
        • Sloan J
        Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.
        J Clin Epidemiol. 2008; 61: 102-109
        • Efron B.
        • Gong G
        A leisurely look at the bootstrap, the jackknife, and cross-validation.
        Am Statistician. 1983; 37: 36-48
        • Hanley J.A.
        • McNeil B.J
        A method of comparing the areas under receiver operating characteristic curves derived from the same cases.
        Radiology. 1983; 148: 839-843
        • Goldin J.G.
        • Kim G.H.J.
        • Tseng C.H.
        • Volkmann E.
        • Furst D.
        • Clements P.
        • et al.
        Longitudinal changes in quantitative interstitial lung disease on CT after immunosuppression in the scleroderma lung study II.
        Annals ATS. 2018;
        • Kim G.H.J.
        • Tashkin D.P.
        • Lo P.
        • Brown M.
        • Volkmann E.
        • Gjertson D.W.
        • et al.
        Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease.
        Arthritis Rheumatol. 2019; (Aug 20)
        • Bocchino M.
        • Bruzzese D.
        • D'Alto M.
        • Argiento P.
        • Borgia A.
        • Capaccio A.
        • et al.
        Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis.
        Sci Rep. 2019; 9 (Jul 1): 9468
        • Adler S.
        • Huscher D.
        • Siegert E.
        • Allanore Y.
        • Czirják L.
        • DelGaldo F.
        • et al.
        Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: results of the Eustar group.
        Arthritis Res Ther. 2018; 20 (30): 17
        • Khanna D.
        • Brown K.K.
        • Clements P.J.
        • Elashoff R.
        • Furst D.E.
        • Goldin G.
        • et al.
        Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
        Clin Exp Rheumatol. 2010; 28: S55-S62
        • Goldin J.
        • Elashoff R.
        • Kim H.J.
        • Yan X.
        • Lynch D.
        • Strollo D.
        • et al.
        Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo.
        Chest. 2009; 136: 1333-1340
        • de Vet H.C.
        • Terluin B.
        • Knol D.
        • Roorda L.D.
        • Mokkink L.B.
        • Ostelo R.W.
        • et al.
        Three ways to quantify uncertainty in individually applied “minimally important change” (MIC) values.
        J Clin Epidemiol. 2010; 63: 37-45
        • Salaffi F.
        • Carotti M.
        • Di Carlo M.
        • Tardella M.
        • Giovagnoni A.
        High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities.
        Medicine (Baltimore). 2019; 98 (Vol:No(e17088)): e17088https://doi.org/10.1097/MD.0000000000017088